胃肠道疾病与菌群治疗

黄子誉; 左涛; 兰平

doi:10.12290/xhyxzz.2022-0208

胃肠道疾病与菌群治疗

doi: 10.12290/xhyxzz.2022-0208

黄子誉¹,
左涛^{1, 2, ,},
兰平^{1, 2, 3, ,}

1.
广东省胃肠病学研究所，广州 510655
2.
中山大学附属第六医院广东省结直肠盆底疾病研究重点实验室，广州 510655
3.
中山大学附属第六医院结直肠肛门外科，广州 510655

基金项目:

国家自然科学基金 U21A20344

国家自然科学基金 82172323

国家自然科学基金 32100134

国家临床重点专科项目；广州市科技计划项目 202206010014

详细信息

通讯作者:
左涛, E-mail: zuot@mail.sysu.edu.cn

兰平, E-mail: lanping@mail.sysu.edu.cn

中图分类号: R37
计量
- 文章访问数: 3594
- HTML全文浏览量: 1115
- PDF下载量: 248
- 被引次数: 0
出版历程
- 收稿日期: 2022-04-14
- 录用日期: 2022-07-21
- 网络出版日期: 2022-08-16
- 刊出日期: 2022-09-30

Gastrointestinal Diseases and Gut Microbiome Therapy

HUANG Ziyu¹,
ZUO Tao^{1, 2
, ,},
LAN Ping^{1, 2, 3
, ,}

1.
Guangdong Institute of Gastroenterology, Guangzhou 510655, China
2.
Guangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Diseases, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou 510655, China
3.
Department of Colorectal Surgery, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou 510655, China

Funds:

National Natural Science Foundation of China U21A20344

National Natural Science Foundation of China 82172323

National Natural Science Foundation of China 32100134

National Key Clinical Discipline; Municipal Key Research and Development Program of Guangzhou 202206010014

More Information

Corresponding author: ZUO Tao, E-mail: zuot@mail.sysu.edu.cn; LAN Ping, E-mail: lanping@mail.sysu.edu.cn

摘要

摘要: 肠道菌群通过其代谢物、分泌物或细胞成分参与调节宿主代谢和免疫，并保护宿主抵抗病原微生物入侵。环境、营养、生活习惯改变以及抗生素滥用等原因均可导致肠道微生态结构和功能失调，进而导致多种疾病。与此同时，肠道菌群亦成为极具潜力的疾病治疗手段。本文将对胃肠道疾病(包括胃肠道感染性疾病、炎症性肠病、肠易激综合征等)与菌群的关系以及基于肠道菌群治疗该类疾病的最新研究成果进行总结，并对肠道菌群在未来疾病预防和干预中的前景作出展望。
- 肠道菌群 /
- 微生态 /
- 胃肠道疾病 /
- 治疗 /
- 粪便微生物移植
Abstract: Gut microbiome regulates host metabolism and immunity via their metabolites, secretions, and cellular components, and protects the host from pathogen invasion. Low diversity and dysfunction of the gut microbiome caused by environmental changes, unhealthy dietary habits and lifestyles, and antibiotics abuse are closely related to disease pathogenesis. Gut microbiome can serve as diagnostic and therapeutic tools for diseases related to gut microbiome dysbiosis. In this article, we aim to review the latest study advances on gut microbiome in the pathogenesis and therapeutics of gastrointestinal diseases, such as Clostridium difficile infection, Helicobacter pylori infection, inflammatory bowel disease, and irritable bowel syndrome, so as to shed light on the prospect of gut microbiome modulations in disease therapies.
- gut microbiome /
- microbiology /
- gastrointestinal diseases /
- therapy /
- fecal microbiota transplantation
注释:

作者贡献：黄子誉负责文献检索及论文撰写；兰平、左涛共同参与论文选题和设计；左涛负责论文修订。

利益冲突：所有作者均声明不存在利益冲突

HTML全文

参考文献(65)

[1]	Kordus SL, Thomas AK, Lacy DB. Clostridioides difficile toxins: mechanisms of action and antitoxin therapeutics[J]. Nat Rev Microbiol, 2022, 20: 285-298. doi: 10.1038/s41579-021-00660-2
[2]	Shen A. Clostridioides difficile Spore Formation and Germination: New Insights and Opportunities for Intervention[J]. Annu Rev Microbiol, 2020, 74: 545-566. doi: 10.1146/annurev-micro-011320-011321
[3]	Simpson M, Frisbee A, Kumar P, et al. Clostridioides difficile Binary Toxin Is Recognized by the Toll-Like Rece-ptor 2/6 Heterodimer to Induce a Nuclear Factor-κB Response[J]. J Infect Dis, 2022, 225: 1296-1300. doi: 10.1093/infdis/jiaa620
[4]	O'connor A, O'morain CA, Ford AC. Population screening and treatment of Helicobacter pylori infection[J]. Nat Rev Gastroenterol Hepatol, 2017, 14: 230-240. doi: 10.1038/nrgastro.2016.195
[5]	Bernardini G, Figura N, Ponzetto A, et al. Application of proteomics to the study of Helicobacter pylori and implications for the clinic[J]. Expert Rev Proteomics, 2017, 14: 477-490. doi: 10.1080/14789450.2017.1331739
[6]	Matsuoka K, Kobayashi T, Ueno F, et al. Evidence-based clinical practice guidelines for inflammatory bowel disease[J]. J Gastroenterol, 2018, 53: 305-353. doi: 10.1007/s00535-018-1439-1
[7]	Aden K, Rehman A, Waschina S, et al. Metabolic Functions of Gut Microbes Associate With Efficacy of Tumor Necrosis Factor Antagonists in Patients With Inflammatory Bowel Diseases[J]. Gastroenterology, 2019, 157: 1279-1292. e1211. doi: 10.1053/j.gastro.2019.07.025
[8]	Rodríguez C, Romero E, Garrido-Sanchez L, et al. Microbiota Insights in Clostridium Difficile Infection and In-flammatory Bowel Disease[J]. Gut Microbes, 2020, 12: 1725220. doi: 10.1080/19490976.2020.1725220
[9]	Franzosa EA, Sirota-Madi A, Avila-Pacheco J, et al. Gut microbiome structure and metabolic activity in inflammatory bowel disease[J]. Nat Microbiol, 2019, 4: 293-305. doi: 10.1038/s41564-018-0306-4
[10]	Haberman Y, Karns R, Dexheimer PJ, et al. Ulcerative colitis mucosal transcriptomes reveal mitochondriopathy and personalized mechanisms underlying disease severity and treatment response[J]. Nat Commun, 2019, 10: 38. doi: 10.1038/s41467-018-07841-3
[11]	Duan R, Zhu S, Wang B, et al. Alterations of Gut Microbiota in Patients With Irritable Bowel Syndrome Based on 16S rRNA-Targeted Sequencing: A Systematic Review[J]. Clin Transl Gastroenterol, 2019, 10: e00012. doi: 10.14309/ctg.0000000000000012
[12]	Zhang Y, Saint Fleur A, Feng H. The development of live biotherapeutics against Clostridioides difficile infection towards reconstituting gut microbiota[J]. Gut Microbes, 2022, 14: 2052698-2052698. doi: 10.1080/19490976.2022.2052698
[13]	Cammarota G, Ianiro G, Kelly CR, et al. International consensus conference on stool banking for faecal microbiota transplantation in clinical practice[J]. Gut, 2019, 68: 2111-2121. doi: 10.1136/gutjnl-2019-319548
[14]	van Nood E, Vrieze A, Nieuwdorp M, et al. Duodenal Infusion of Donor Feces for Recurrent Clostridium difficile[J]. N Eng J Med, 2013, 368: 407-415. doi: 10.1056/NEJMoa1205037
[15]	Brown JRM, Flemer B, Joyce SA, et al. Changes in microbiota composition, bile and fatty acid metabolism, in successful faecal microbiota transplantation for Clostridioides difficile infection[J]. BMC Gastroenterol, 2018, 18: 131. doi: 10.1186/s12876-018-0860-5
[16]	Feuerstadt P, Louie TJ, Lashner B, et al. SER-109, an Oral Microbiome Therapy for Recurrent Clostridioides difficile Infection[J]. N Engl J Med, 2022, 386: 220-229. doi: 10.1056/NEJMoa2106516
[17]	Zuo T, Wong SH, Cheung CP, et al. Gut fungal dysbiosis correlates with reduced efficacy of fecal microbiota transplantation in Clostridium difficile infection[J]. Nat commun, 2018, 9: 1-11. doi: 10.1038/s41467-017-02088-w
[18]	Paramsothy S, Kamm MA, Kaakoush NO, et al. Multidonor intensive faecal microbiota transplantation for active ulcerative colitis: a randomised placebo-controlled trial[J]. Lancet, 2017, 389: 1218-1228. doi: 10.1016/S0140-6736(17)30182-4
[19]	Costello SP, Waters O, Bryant RV, et al. Short duration, low intensity, pooled fecal microbiota transplantation induces remission in patients with mild-moderately active ulcerative colitis: a randomised controlled trial[J]. Gastroenterology, 2017, 152: S198-S199.
[20]	Sokol H, Landman C, Seksik P, et al. Fecal microbiota transplantation to maintain remission in Crohn's disease: a pilot randomized controlled study[J]. Microbiome, 2020, 8: 12. doi: 10.1186/s40168-020-0792-5
[21]	Johnsen PH, Hilpüsch F, Cavanagh JP, et al. Faecal microbiota transplantation versus placebo for moderate-to-severe irritable bowel syndrome: a double-blind, randomised, placebo-controlled, parallel-group, single-centre trial[J]. Lancet Gastroenterol Hepatol, 2018, 3: 17-24. doi: 10.1016/S2468-1253(17)30338-2
[22]	Halkjær SI, Christensen AH, Lo BZS, et al. Faecal microbiota transplantation alters gut microbiota in patients with irritable bowel syndrome: results from a randomised, double-blind placebo-controlled study[J]. Gut, 2018, 67: 2107-2115. doi: 10.1136/gutjnl-2018-316434
[23]	Hill C, Guarner F, Reid G, et al. The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic[J]. Nat Rev Gastroenterol Hepatol, 2014, 11: 506-514. doi: 10.1038/nrgastro.2014.66
[24]	Nobutani K, Sawada D, Fujiwara S, et al. The effects of administration of the Lactobacillus gasseri strain CP2305 on quality of life, clinical symptoms and changes in gene expression in patients with irritable bowel syndrome[J]. J Appl Microbiol, 2017, 122: 212-224. doi: 10.1111/jam.13329
[25]	Libertucci J, Young VB. The role of the microbiota in infectious diseases[J]. Nat Microbiol, 2019, 4: 35-45. doi: 10.1038/s41564-018-0278-4
[26]	Singh RK, Chang HW, Yan D, et al. Influence of diet on the gut microbiome and implications for human health[J]. J Transl Med, 2017, 15: 73. doi: 10.1186/s12967-017-1175-y
[27]	van der Hee B, Wells JM. Microbial Regulation of Host Physiology by Short-chain Fatty Acids[J]. Trends Microbiol, 2021, 29: 700-712. doi: 10.1016/j.tim.2021.02.001
[28]	Abraham BP, Quigley EM. Probiotics in inflammatory bowel disease[J]. Gastroenterol Clin, 2017, 46: 769-782. doi: 10.1016/j.gtc.2017.08.003
[29]	Ghavami SB, Yadegar A, Aghdaei HA, et al. Immunomodulation and generation of tolerogenic dendritic cells by probiotic bacteria in patients with inflammatory bowel disease[J]. Int J Mol Sci, 2020, 21: 6266. doi: 10.3390/ijms21176266
[30]	Wu L, Wang Z, Sun G, et al. Effects of anti-H. pylori triple therapy and a probiotic complex on intestinal microbiota in duodenal ulcer[J]. Sci Rep, 2019, 9: 12874. doi: 10.1038/s41598-019-49415-3
[31]	Alba C, Blanco A, Alarcón T. Antibiotic resistance in Helicobacter pylori[J]. Curr Opin Infect Dis, 2017, 30: 489-497. doi: 10.1097/QCO.0000000000000396
[32]	Sykora J, Valeckova K, Amlerova J, et al. Effects of a specially designed fermented milk product containing prob iotic Lactobacillus casei DN-114 001 and the eradication of H. pylori in children: a prospective randomized double-blind study[J]. J Clin Gastroenterol, 39: 692-698. doi: 10.1097/01.mcg.0000173855.77191.44
[33]	Deguchi R, Nakaminami H, Rimbara E, et al. Effect of pretreatment with Lactobacillus gasseri OLL2716 on first-line Helicobacter pylori eradication therapy[J]. J Gastroenterol Hepatol, 2012, 27: 888-892. doi: 10.1111/j.1440-1746.2011.06985.x
[34]	Hegazy SK, El-Bedewy MM. Effect of probiotics on pro-inflammatory cytokines and NF-κB activation in ulcerative colitis[J]. World J Gastroenterol, 2010, 16: 4145. doi: 10.3748/wjg.v16.i33.4145
[35]	Imaoka A, Shima T, Kato K, et al. Anti-inflammatory activity of probiotic Bifidobacterium: enhancement of IL-10 production in peripheral blood mononuclear cells from ulcerati ve colitis patients and inhibition of IL-8 secretion in HT-29 cells[J]. World J Gastroenterol, 2008, 14: 2511. doi: 10.3748/wjg.14.2511
[36]	Palumbo VD, Romeo M, Marino Gammazza A, et al. The long-term effects of probiotics in the therapy of ulcerative colitis: A clinical study[J]. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub, 2016, 160: 372-377. doi: 10.5507/bp.2016.044
[37]	Generoso SV, Viana ML, Santos RG, et al. Protection against increased intestinal permeability and bacterial translocation induced by intestinal obstruction in mice treated with viable and heat-killed Saccharomyces boulardii[J]. Eur J Nutr, 2011, 50: 261-269. doi: 10.1007/s00394-010-0134-7
[38]	Bourreille A, Cadiot G, Le Dreau G, et al. Saccharomyces boulardii does not prevent relapse of Crohn's disease[J]. Clin Gastroenterol Hepatol, 2013, 11: 982-987. doi: 10.1016/j.cgh.2013.02.021
[39]	Zhang MY, Zhang CC, Zhao JX, et al. Meta-analysis of the efficacy of probiotic-supplemented therapy on the eradication of H. pylori and incidence of therapy-associated side effects[J]. Microb Pathog, 2020, 147: 104403. doi: 10.1016/j.micpath.2020.104403
[40]	Yoon JS, Sohn W, Lee OY, et al. Effect of multispecies probiotics on irritable bowel syndrome: A randomized, double-blind, placebo-controlled trial[J]. J Gastroenterol Hepatol, 2014, 29: 52-59. doi: 10.1111/jgh.12322
[41]	Barker AK, Duster M, Valentine S, et al. A randomized controlled trial of probiotics for Clostridium difficile infection in adults (PICO)[J]. J Antimicrob Chemother, 2017, 72: 3177-3180. doi: 10.1093/jac/dkx254
[42]	Gibson GR, Hutkins R, Sanders ME, et al. Expert consensus document: The International Scientific Association for Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of prebiotics[J]. Nat Rev Gastroenterol Hepatol, 2017, 14: 491-502. doi: 10.1038/nrgastro.2017.75
[43]	Thilakarathna WW, Langille MG, Rupasinghe HV. Polyphenol-based prebiotics and synbiotics: potential for cancer chemoprevention[J]. Cur Opin Food Sci, 2018, 20: 51-57. doi: 10.1016/j.cofs.2018.02.011
[44]	De Almeida CV, de Camargo MR, Russo E, et al. Role of diet and gut microbiota on colorectal cancer immunomodulation[J]. World J Gastroenterol, 2019, 25: 151.
[45]	Zhang XF, Guan XX, Tang YJ, et al. Clinical effects and gut microbiota changes of using probiotics, prebiotics or synbiotics in inflammatory bowel disease: a systematic review and meta-analysis[J]. Eur J Nutr, 2021, 60: 2855-2875. doi: 10.1007/s00394-021-02503-5
[46]	Niv E, Halak A, Tiommny E, et al. Randomized clinical study: Partially hydrolyzed guar gum (PHGG) versus placebo in the treatment of patients with irritable bowel syndrome[J]. Nutr Metab (Lond), 2016, 13: 10. doi: 10.1186/s12986-016-0070-5
[47]	Azpiroz F, Dubray C, Bernalier-Donadille A, et al. Effects of scFOS on the composition of fecal microbiota and anxiety in patients with irritable bowel syndrome: a randomized, double blind, placebo controlled study[J]. Neurogastroenterol Motil, 2017, 29: e12911. doi: 10.1111/nmo.12911
[48]	Swanson KS, Gibson GR, Hutkins R, et al. The Interna-tional Scientific Association for Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of synbiotics[J]. Nat Rev Gastroenterol Hepatol, 2020, 17: 687-701. doi: 10.1038/s41575-020-0344-2
[49]	Steed H, Macfarlane GT, Blackett KL, et al. Clinical trial: the microbiological and immunological effects of synbiotic consumption-a randomized double-blind placebo-controlled study in active Crohn's disease[J]. Aliment Pharmacol Ther, 2010, 32: 872-883. doi: 10.1111/j.1365-2036.2010.04417.x
[50]	Furrie E, Macfarlane S, Kennedy A, et al. Synbiotic therapy (Bifidobacterium longum/Synergy 1) initiates resolution of inflammation in patients with active ulcerative colitis: a randomised controlled pilot trial[J]. Gut, 2005, 54: 242-249. doi: 10.1136/gut.2004.044834
[51]	Fujimori S, Gudis K, Mitsui K, et al. A randomized controlled trial on the efficacy of synbiotic versus probiotic or prebiotic treatment to improve the quality of life in patients with ulcerative colitis[J]. Nutrition, 2009, 25: 520-525. doi: 10.1016/j.nut.2008.11.017
[52]	Moser AM, Spindelboeck W, Halwachs B, et al. Effects of an oral synbiotic on the gastrointestinal immune system and microbiota in patients with diarrhea-predominant irritable bowel syndrome[J]. Eur J Nutr, 2019, 58: 2767-2778.
[53]	Skrzydło-Radomańska B, Prozorow-Król B, Cichoż-Lach H, et al. The Effectiveness of Synbiotic Preparation Containing Lactobacillus and Bifidobacterium Probiotic Strains and Short Chain Fructooligosaccharides in Patients with Diarrhea Predominant Irritable Bowel Syndrome—A Randomized Double-Blind, Placebo-Controlled Study[J]. Nutrients, 2020, 12: 1999. doi: 10.3390/nu12071999
[54]	Pourmasoumi M, Najafgholizadeh A, Hadi A, et al. The effect of synbiotics in improving Helicobacter pylori eradication: A systematic review and meta-analysis[J]. Complement Ther Med, 2019, 43: 36-43. doi: 10.1016/j.ctim.2019.01.005
[55]	Salminen S, Collado MC, Endo A, et al. The International Scientific Association of Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of postbiotics[J]. Nat Rev Gastroenterol Hepatol, 2021, 18: 649-667. doi: 10.1038/s41575-021-00440-6
[56]	Sun Z, Harris HM, McCann A, et al. Expanding the biotechnology potential of Lactobacilli through comparative genomics of 213 strains and associated genera[J]. Nat Commun, 2015, 6: 8322. doi: 10.1038/ncomms9322
[57]	Gao J, Li Y, Wan Y, et al. A novel postbiotic from Lactobacillus rhamnosus GG with a beneficial effect on intestinal barrier function[J]. Front Microbiol, 2019, 10: 477. doi: 10.3389/fmicb.2019.00477
[58]	Morita N, Umemoto E, Fujita S, et al. GPR31-dependent dendrite protrusion of intestinal CX3CR1⁺ cells by bacterial metabolites[J]. Nature, 2019, 566: 110-114. doi: 10.1038/s41586-019-0884-1
[59]	Mullish BH, McDonald JA, Pechlivanis A, et al. Microbial bile salt hydrolases mediate the efficacy of faecal microbiota transplant in the treatment of recurrent Clostridioides difficile infection[J]. Gut, 2019, 68: 1791-1800. doi: 10.1136/gutjnl-2018-317842
[60]	Engevik MA, Luck B, Visuthranukul C, et al. Human-derived Bifidobacterium dentium modulates the mammalian serotonergic system and gut-brain axis[J]. Cell Mol Gastroenterol Hepatol, 2021, 11: 221-248. doi: 10.1016/j.jcmgh.2020.08.002
[61]	Canducci F, Armuzzi A, Cremonini F, et al. A lyophilized and inactivated culture of Lactobacillus acidophilus increases Helicobacter pylori eradication rates[J]. Aliment Pharmacol Ther, 2000, 14: 1625-1629. doi: 10.1046/j.1365-2036.2000.00885.x
[62]	Mehling H, Busjahn A. Non-Viable Lactobacillus reuteri DSMZ 17648 (Pylopass^TM) as a New Approach to Helicobacter pylori Control in Humans[J]. Nutrients, 2013, 5: 3062-3073. doi: 10.3390/nu5083062
[63]	Mullish BH, McDonald JAK, Pechlivanis A, et al. Micro-bial bile salt hydrolases mediate the efficacy of faecal microbiota transplant in the treatment of recurrent < em > Clostridioides difficile infection[J]. Gut, 2019, 68: 1791-1800. doi: 10.1136/gutjnl-2018-317842
[64]	Andresen V, Gschossmann J, Layer P. Heat-inactivated Bifidobacterium bifidum MIMBb75 (SYN-HI-001) in the treatment of irritable bowel syndrome: a multicentre, randomised, double-blind, placebo-controlled clinical trial[J]. Lancet Gastroenterol Hepatol, 2020, 5: 658-666. doi: 10.1016/S2468-1253(20)30056-X
[65]	Facchin S, Vitulo N, Calgaro M, et al. Microbiota changes induced by microencapsulated sodium butyrate in patients with inflammatory bowel disease[J]. Neurogastroenterol Motil, 2020, 32: e13914.

施引文献

资源附件(0)

访问统计

点击查看大图

计量

文章访问数: 3594
HTML全文浏览量: 1115
PDF下载量: 248
被引次数: 0

姓名
邮箱
手机号码
标题
留言内容
验证码

地址：	北京市东城区帅府园1号北京协和医院老楼7号楼 3层302室《协和医学杂志》编辑部
电话：	010-69154261/4262
E - mail：	medj@pumch.cn mjpumch@126.com
期刊网站版权所有：	《协和医学杂志》编辑部京ICP备 11002662

留言板

胃肠道疾病与菌群治疗

doi: 10.12290/xhyxzz.2022-0208

通讯作者:
左涛, E-mail: zuot@mail.sysu.edu.cn

兰平, E-mail: lanping@mail.sysu.edu.cn

计量

Gastrointestinal Diseases and Gut Microbiome Therapy

Corresponding author: ZUO Tao, E-mail: zuot@mail.sysu.edu.cn; LAN Ping, E-mail: lanping@mail.sysu.edu.cn

计量

目录

留言板

胃肠道疾病与菌群治疗

doi: 10.12290/xhyxzz.2022-0208

通讯作者: 左涛, E-mail: zuot@mail.sysu.edu.cn 兰平, E-mail: lanping@mail.sysu.edu.cn

计量

出版历程

Gastrointestinal Diseases and Gut Microbiome Therapy

Corresponding author: ZUO Tao, E-mail: zuot@mail.sysu.edu.cn; LAN Ping, E-mail: lanping@mail.sysu.edu.cn

计量

出版历程

目录

通讯作者:
左涛, E-mail: zuot@mail.sysu.edu.cn

兰平, E-mail: lanping@mail.sysu.edu.cn